JP6309019B2 - 甲状腺腫瘍を診断するための組成物および方法 - Google Patents
甲状腺腫瘍を診断するための組成物および方法 Download PDFInfo
- Publication number
- JP6309019B2 JP6309019B2 JP2015544190A JP2015544190A JP6309019B2 JP 6309019 B2 JP6309019 B2 JP 6309019B2 JP 2015544190 A JP2015544190 A JP 2015544190A JP 2015544190 A JP2015544190 A JP 2015544190A JP 6309019 B2 JP6309019 B2 JP 6309019B2
- Authority
- JP
- Japan
- Prior art keywords
- gene
- thyroid
- tissue sample
- sample
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 329
- 208000024770 Thyroid neoplasm Diseases 0.000 title claims description 102
- 239000000203 mixture Substances 0.000 title description 21
- 208000013076 thyroid tumor Diseases 0.000 title description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 694
- 239000000523 sample Substances 0.000 claims description 348
- 230000014509 gene expression Effects 0.000 claims description 331
- 210000001685 thyroid gland Anatomy 0.000 claims description 210
- 239000012472 biological sample Substances 0.000 claims description 132
- 206010028980 Neoplasm Diseases 0.000 claims description 104
- 201000011510 cancer Diseases 0.000 claims description 99
- 108091034117 Oligonucleotide Proteins 0.000 claims description 93
- 239000003153 chemical reaction reagent Substances 0.000 claims description 80
- 201000002510 thyroid cancer Diseases 0.000 claims description 77
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims description 76
- 238000004458 analytical method Methods 0.000 claims description 73
- 101150058049 car gene Proteins 0.000 claims description 73
- 101150037720 CCR7 gene Proteins 0.000 claims description 69
- 150000007523 nucleic acids Chemical class 0.000 claims description 69
- 101150077124 CXCL10 gene Proteins 0.000 claims description 63
- 102000039446 nucleic acids Human genes 0.000 claims description 61
- 108020004707 nucleic acids Proteins 0.000 claims description 61
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 101150019010 CCR3 gene Proteins 0.000 claims description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 229920001184 polypeptide Polymers 0.000 claims description 47
- 101150004010 CXCR3 gene Proteins 0.000 claims description 41
- 108010018924 Heme Oxygenase-1 Proteins 0.000 claims description 41
- 238000012360 testing method Methods 0.000 claims description 39
- 101150051753 gene 7 gene Proteins 0.000 claims description 35
- 102100028006 Heme oxygenase 1 Human genes 0.000 claims description 33
- 230000002380 cytological effect Effects 0.000 claims description 26
- 230000035945 sensitivity Effects 0.000 claims description 25
- 238000001356 surgical procedure Methods 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 10
- 101710183399 Keratin, type I cytoskeletal 19 Proteins 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 238000001794 hormone therapy Methods 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 108700026220 vif Genes Proteins 0.000 claims 2
- 239000000047 product Substances 0.000 description 389
- 210000001519 tissue Anatomy 0.000 description 210
- 239000002773 nucleotide Substances 0.000 description 120
- 125000003729 nucleotide group Chemical group 0.000 description 120
- 238000003556 assay Methods 0.000 description 76
- 238000004422 calculation algorithm Methods 0.000 description 75
- 239000002157 polynucleotide Substances 0.000 description 66
- 108091033319 polynucleotide Proteins 0.000 description 65
- 102000040430 polynucleotide Human genes 0.000 description 65
- 239000013615 primer Substances 0.000 description 55
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 50
- 238000003199 nucleic acid amplification method Methods 0.000 description 46
- 230000003321 amplification Effects 0.000 description 43
- 239000000090 biomarker Substances 0.000 description 41
- 101000892366 Homo sapiens Actin filament-associated protein 1-like 2 Proteins 0.000 description 39
- 108020004999 messenger RNA Proteins 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 34
- 238000009396 hybridization Methods 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 238000002493 microarray Methods 0.000 description 28
- 238000003752 polymerase chain reaction Methods 0.000 description 28
- 208000009453 Thyroid Nodule Diseases 0.000 description 27
- 230000003211 malignant effect Effects 0.000 description 25
- 108020004635 Complementary DNA Proteins 0.000 description 24
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 24
- 230000000295 complement effect Effects 0.000 description 24
- 238000010804 cDNA synthesis Methods 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 22
- 238000003753 real-time PCR Methods 0.000 description 21
- 239000000758 substrate Substances 0.000 description 20
- 230000008569 process Effects 0.000 description 17
- 238000001574 biopsy Methods 0.000 description 16
- 238000003745 diagnosis Methods 0.000 description 16
- 238000002405 diagnostic procedure Methods 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 230000027455 binding Effects 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- -1 rRNA Proteins 0.000 description 11
- 238000012340 reverse transcriptase PCR Methods 0.000 description 11
- 238000012549 training Methods 0.000 description 11
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 10
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 10
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 208000003200 Adenoma Diseases 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000013068 control sample Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000003325 follicular Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 102100034343 Integrase Human genes 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 7
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 7
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 201000004260 follicular adenoma Diseases 0.000 description 7
- 208000030878 follicular thyroid adenoma Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000002987 primer (paints) Substances 0.000 description 7
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 206010004412 Benign neoplasm of thyroid gland Diseases 0.000 description 6
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 6
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 6
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 6
- 238000013188 needle biopsy Methods 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 238000012706 support-vector machine Methods 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 5
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 5
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 5
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 5
- 108060005251 Nectin Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000002096 quantum dot Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000003196 serial analysis of gene expression Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100040634 Actin filament-associated protein 1-like 2 Human genes 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 208000017333 follicular variant thyroid gland papillary carcinoma Diseases 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012882 sequential analysis Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101150022250 CXCL11 gene Proteins 0.000 description 3
- 101150115558 CXCL9 gene Proteins 0.000 description 3
- 101150066398 CXCR4 gene Proteins 0.000 description 3
- 102100040836 Claudin-1 Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000749331 Homo sapiens Claudin-1 Proteins 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010054107 Nodule Diseases 0.000 description 3
- 238000002944 PCR assay Methods 0.000 description 3
- 102100030304 Platelet factor 4 Human genes 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000001744 histochemical effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011273 incision biopsy Methods 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 238000007388 punch biopsy Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000002356 Nectin Human genes 0.000 description 2
- 238000010826 Nissl staining Methods 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000012352 Spearman correlation analysis Methods 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000002986 genetic algorithm method Methods 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000007620 mathematical function Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013643 reference control Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 2
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical compound CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 1
- UKLNSYRWDXRTER-UHFFFAOYSA-N 7-isocyanato-3-phenylchromen-2-one Chemical compound O=C1OC2=CC(N=C=O)=CC=C2C=C1C1=CC=CC=C1 UKLNSYRWDXRTER-UHFFFAOYSA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- NLSUMBWPPJUVST-UHFFFAOYSA-N 9-isothiocyanatoacridine Chemical compound C1=CC=C2C(N=C=S)=C(C=CC=C3)C3=NC2=C1 NLSUMBWPPJUVST-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 239000012118 Alexa Fluor 750 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108050001427 Avidin/streptavidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150014851 CLDN1 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 101800001318 Capsid protein VP4 Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 229910000673 Indium arsenide Inorganic materials 0.000 description 1
- GPXJNWSHGFTCBW-UHFFFAOYSA-N Indium phosphide Chemical compound [In]#P GPXJNWSHGFTCBW-UHFFFAOYSA-N 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 description 1
- 108010066370 Keratin-20 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100028680 Protein patched homolog 1 Human genes 0.000 description 1
- 101710161390 Protein patched homolog 1 Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 101150077804 TIMP1 gene Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 102000014267 Thyroid peroxidases Human genes 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000012880 independent component analysis Methods 0.000 description 1
- RPQDHPTXJYYUPQ-UHFFFAOYSA-N indium arsenide Chemical compound [In]#[As] RPQDHPTXJYYUPQ-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000000951 ion mobility spectrometry-mass spectrometry Methods 0.000 description 1
- 238000001871 ion mobility spectroscopy Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001921 nucleic acid quantification Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical group 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000011524 similarity measure Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/046—Thyroid disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730391P | 2012-11-27 | 2012-11-27 | |
| US61/730,391 | 2012-11-27 | ||
| US201361775419P | 2013-03-08 | 2013-03-08 | |
| US61/775,419 | 2013-03-08 | ||
| PCT/US2013/071970 WO2014085434A1 (en) | 2012-11-27 | 2013-11-26 | Compositions and methods for diagnosing thyroid tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505247A JP2016505247A (ja) | 2016-02-25 |
| JP2016505247A5 JP2016505247A5 (enExample) | 2016-12-22 |
| JP6309019B2 true JP6309019B2 (ja) | 2018-04-11 |
Family
ID=49880965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544190A Active JP6309019B2 (ja) | 2012-11-27 | 2013-11-26 | 甲状腺腫瘍を診断するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10260103B2 (enExample) |
| EP (1) | EP2925886B1 (enExample) |
| JP (1) | JP6309019B2 (enExample) |
| KR (1) | KR102174578B1 (enExample) |
| CN (1) | CN104937111B (enExample) |
| AU (1) | AU2013352339B2 (enExample) |
| BR (1) | BR112015012239B1 (enExample) |
| CA (1) | CA2892822C (enExample) |
| MX (1) | MX367366B (enExample) |
| NZ (1) | NZ709167A (enExample) |
| WO (1) | WO2014085434A1 (enExample) |
| ZA (1) | ZA201504663B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| EP2806054A1 (en) | 2008-05-28 | 2014-11-26 | Genomedx Biosciences Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| JP6078339B2 (ja) | 2009-05-07 | 2017-02-08 | ベラサイト インコーポレイテッド | 甲状腺状態の診断のための方法および組成物 |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| WO2013090620A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| ES2945036T3 (es) | 2012-08-16 | 2023-06-28 | Veracyte Sd Inc | Pronóstico del cáncer de próstata mediante biomarcadores |
| EP2925886B1 (en) | 2012-11-27 | 2019-04-24 | Pontificia Universidad Católica de Chile | Compositions and methods for diagnosing thyroid tumors |
| US10526655B2 (en) | 2013-03-14 | 2020-01-07 | Veracyte, Inc. | Methods for evaluating COPD status |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| EP3770274A1 (en) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| JP6144314B2 (ja) * | 2015-10-30 | 2017-06-07 | 株式会社Ｕｂｉｃ | データ分類システム，方法，プログラムおよびその記録媒体 |
| EP3397766B1 (en) * | 2015-12-31 | 2023-05-17 | Quest Diagnostics Investments LLC | Compositions and methods for screening mutations in thyroid cancer |
| US11486873B2 (en) | 2016-03-31 | 2022-11-01 | Ontera Inc. | Multipore determination of fractional abundance of polynucleotide sequences in a sample |
| US11414708B2 (en) | 2016-08-24 | 2022-08-16 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| EP3496859B1 (en) | 2016-09-02 | 2024-01-10 | Board of Regents, The University of Texas System | Collection probe and methods for the use thereof |
| CN112213372A (zh) * | 2016-10-24 | 2021-01-12 | 奥特拉公司 | 样品中多核苷酸序列的分数丰度 |
| AU2018210695B2 (en) | 2017-01-20 | 2024-07-18 | The University Of British Columbia | Molecular subtyping, prognosis, and treatment of bladder cancer |
| US11873532B2 (en) | 2017-03-09 | 2024-01-16 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| WO2018205035A1 (en) | 2017-05-12 | 2018-11-15 | Genomedx Biosciences, Inc | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| CN111868260B (zh) | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| CA3083260A1 (en) | 2017-11-27 | 2019-05-31 | Board Of Regents, The University Of Texas System | Minimally invasive collection probe and methods for the use thereof |
| EP4585903A3 (en) * | 2018-02-23 | 2025-10-29 | Board of Regents, The University of Texas System | Tissue analysis by mass spectrometry |
| CN109457032B (zh) * | 2018-12-20 | 2022-04-12 | 北京优迅医学检验实验室有限公司 | 甲状腺癌分子诊断试剂盒 |
| EP3914891A4 (en) | 2019-01-25 | 2022-09-28 | Board of Regents, The University of Texas System | DEVICE AND METHOD FOR CLEANING AND/OR REPLACING MEDICAL DEVICES |
| CN109847072A (zh) * | 2019-02-27 | 2019-06-07 | 四川大学华西医院 | 一种甲状旁腺血供检测试剂盒 |
| RU2712080C1 (ru) * | 2019-05-14 | 2020-01-24 | Федеральное государственное автономное образовательное учреждение высшего образования "Дальневосточный федеральный университет" (ДВФУ) | Способ проведения цитологического исследования при дифференциальной диагностике узловых образований щитовидной железы |
| US11869661B2 (en) | 2019-05-22 | 2024-01-09 | Grail, Llc | Systems and methods for determining whether a subject has a cancer condition using transfer learning |
| WO2021138661A1 (en) * | 2020-01-03 | 2021-07-08 | The University Of Toledo | Stratifying risk of malignancy in indeterminate thyroid nodules and immuno-genomic markers for early detection of thyroid cancer |
| KR102639140B1 (ko) * | 2020-08-14 | 2024-02-20 | 연세대학교 산학협력단 | 조직 검사 방법 및 조직 검사 장치 |
| EP4269613A4 (en) | 2020-12-24 | 2025-02-12 | Pontificia Universidad Católica De Chile | IN VITRO METHODS FOR DIAGNOSIS AND PREDICTION OF THE AGGRESSIVENESS OF THYROID CANCER |
| EP4023770A1 (en) | 2021-01-05 | 2022-07-06 | Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach | A method of examining genes for the diagnosis of thyroid tumors, a set for the diagnosis of thyroid tumors and application |
| TWI843989B (zh) | 2021-02-19 | 2024-06-01 | 美商美威高能離子醫療系統公司 | 用於粒子治療系統之支架 |
| EP4317458A4 (en) * | 2021-03-30 | 2025-03-05 | Nippon Medical School Foundation | FOLLICULAR THYROID CANCER-SPECIFIC MARKER |
| CN115807081A (zh) * | 2021-09-15 | 2023-03-17 | 江苏鹍远生物技术有限公司 | 诊断甲状腺癌的基因标志物及其用途 |
| EP4303324A1 (en) | 2022-07-05 | 2024-01-10 | Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach | A method of distinguishing between benign and malignant thyroid nodules |
| EP4303323B1 (en) | 2022-07-05 | 2025-02-19 | Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach | A method differentiating benign and malignant tyroid nodules |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5766960A (en) | 1987-07-27 | 1998-06-16 | Australian Membrane And Biotechnology Research Institute | Receptor membranes |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
| US5856092A (en) | 1989-02-13 | 1999-01-05 | Geneco Pty Ltd | Detection of a nucleic acid sequence or a change therein |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US6309822B1 (en) | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
| US5925525A (en) | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
| US5871928A (en) | 1989-06-07 | 1999-02-16 | Fodor; Stephen P. A. | Methods for nucleic acid analysis |
| ATE282716T1 (de) | 1989-07-11 | 2004-12-15 | Gen Probe Inc | Verfahren zur amplifikation von nukleinsäuresequenzen |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
| US5936731A (en) | 1991-02-22 | 1999-08-10 | Applied Spectral Imaging Ltd. | Method for simultaneous detection of multiple fluorophores for in situ hybridization and chromosome painting |
| US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| AU7212494A (en) | 1993-06-25 | 1995-01-17 | Affymax Technologies N.V. | Hybridization and sequencing of nucleic acids |
| US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
| US6090555A (en) | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
| JPH09510351A (ja) | 1994-03-16 | 1997-10-21 | ジェン−プローブ・インコーポレイテッド | 等温鎖置換核酸増幅法 |
| US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US6287850B1 (en) | 1995-06-07 | 2001-09-11 | Affymetrix, Inc. | Bioarray chip reaction apparatus and its manufacture |
| US6379897B1 (en) | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
| US5843655A (en) | 1995-09-18 | 1998-12-01 | Affymetrix, Inc. | Methods for testing oligonucleotide arrays |
| US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US5837196A (en) | 1996-01-26 | 1998-11-17 | The Regents Of The University Of California | High density array fabrication and readout method for a fiber optic biosensor |
| AU2189397A (en) | 1996-02-08 | 1997-08-28 | Affymetrix, Inc. | Chip-based speciation and phenotypic characterization of microorganisms |
| US6114122A (en) | 1996-03-26 | 2000-09-05 | Affymetrix, Inc. | Fluidics station with a mounting system and method of using |
| US6238866B1 (en) | 1996-04-16 | 2001-05-29 | The United States Of America As Represented By The Secretary Of The Army | Detector for nucleic acid typing and methods of using the same |
| GB9609262D0 (en) | 1996-05-02 | 1996-07-03 | Isis Innovation | Peptide library and method |
| US5958342A (en) | 1996-05-17 | 1999-09-28 | Incyte Pharmaceuticals, Inc. | Jet droplet device |
| US5853993A (en) | 1996-10-21 | 1998-12-29 | Hewlett-Packard Company | Signal enhancement method and kit |
| DE69727489T2 (de) | 1996-11-06 | 2004-11-25 | Sequenom, Inc., San Diego | Verfahren zur massenspektrometrie |
| US5804386A (en) | 1997-01-15 | 1998-09-08 | Incyte Pharmaceuticals, Inc. | Sets of labeled energy transfer fluorescent primers and their use in multi component analysis |
| US6309824B1 (en) | 1997-01-16 | 2001-10-30 | Hyseq, Inc. | Methods for analyzing a target nucleic acid using immobilized heterogeneous mixtures of oligonucleotide probes |
| DE69833758T2 (de) | 1997-06-13 | 2006-08-31 | Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara | Verfahren zur erkennung von genpolymorphismen und allelexpression unter verwendung von sondenchips |
| US6333179B1 (en) | 1997-06-20 | 2001-12-25 | Affymetrix, Inc. | Methods and compositions for multiplex amplification of nucleic acids |
| US6420108B2 (en) | 1998-02-09 | 2002-07-16 | Affymetrix, Inc. | Computer-aided display for comparative gene expression |
| WO1999005591A2 (en) | 1997-07-25 | 1999-02-04 | Affymetrix, Inc. | Method and apparatus for providing a bioinformatics database |
| CA2299625A1 (en) | 1997-08-15 | 1999-02-25 | Affymetrix, Inc. | Polymorphism detection utilizing clustering analysis |
| US6511803B1 (en) | 1997-10-10 | 2003-01-28 | President And Fellows Of Harvard College | Replica amplification of nucleic acid arrays |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US6054274A (en) | 1997-11-12 | 2000-04-25 | Hewlett-Packard Company | Method of amplifying the signal of target nucleic acid sequence analyte |
| US6013449A (en) | 1997-11-26 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Probe-based analysis of heterozygous mutations using two-color labelling |
| EP1051624A4 (en) | 1998-01-29 | 2002-05-02 | Glaucus Proteomics B V | HIGH DENSITY MATERIALS FOR PROTEOM ANALYSIS AND METHOD AND COMPOSITIONS THEREFOR |
| WO1999039001A2 (en) | 1998-02-02 | 1999-08-05 | Amersham Pharmacia Biotech Ab | Nucleic acid analysis method |
| US6083726A (en) | 1998-02-03 | 2000-07-04 | Lucent Technologies, Inc. | Methods for polynucleotide synthesis and articles for polynucleotide hybridization |
| JP2002502977A (ja) | 1998-02-04 | 2002-01-29 | インビトロジェン コーポレイション | マイクロアレイとその使用 |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
| US6284497B1 (en) | 1998-04-09 | 2001-09-04 | Trustees Of Boston University | Nucleic acid arrays and methods of synthesis |
| US6525185B1 (en) | 1998-05-07 | 2003-02-25 | Affymetrix, Inc. | Polymorphisms associated with hypertension |
| US6268210B1 (en) | 1998-05-27 | 2001-07-31 | Hyseq, Inc. | Sandwich arrays of biological compounds |
| US6306643B1 (en) | 1998-08-24 | 2001-10-23 | Affymetrix, Inc. | Methods of using an array of pooled probes in genetic analysis |
| US6185561B1 (en) | 1998-09-17 | 2001-02-06 | Affymetrix, Inc. | Method and apparatus for providing and expression data mining database |
| US6203989B1 (en) | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
| US6316193B1 (en) | 1998-10-06 | 2001-11-13 | Origene Technologies, Inc. | Rapid-screen cDNA library panels |
| US6262216B1 (en) | 1998-10-13 | 2001-07-17 | Affymetrix, Inc. | Functionalized silicon compounds and methods for their synthesis and use |
| WO2000024939A1 (en) | 1998-10-27 | 2000-05-04 | Affymetrix, Inc. | Complexity management and analysis of genomic dna |
| US6263287B1 (en) | 1998-11-12 | 2001-07-17 | Scios Inc. | Systems for the analysis of gene expression data |
| US6309828B1 (en) | 1998-11-18 | 2001-10-30 | Agilent Technologies, Inc. | Method and apparatus for fabricating replicate arrays of nucleic acid molecules |
| US6245518B1 (en) | 1998-12-11 | 2001-06-12 | Hyseq, Inc. | Polynucleotide arrays and methods of making and using the same |
| US6351712B1 (en) | 1998-12-28 | 2002-02-26 | Rosetta Inpharmatics, Inc. | Statistical combining of cell expression profiles |
| AU2965500A (en) | 1999-01-15 | 2000-08-01 | Gene Logic, Inc. | Immobilized nucleic acid hybridization reagent and method |
| US6251601B1 (en) | 1999-02-02 | 2001-06-26 | Vysis, Inc. | Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays |
| US6329145B1 (en) | 1999-02-09 | 2001-12-11 | Gilead Science, Inc. | Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand |
| US6177248B1 (en) | 1999-02-24 | 2001-01-23 | Affymetrix, Inc. | Downstream genes of tumor suppressor WT1 |
| WO2000054046A2 (en) | 1999-03-10 | 2000-09-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Universal protein array system |
| WO2000061806A2 (en) | 1999-04-09 | 2000-10-19 | Arcturus Engineering, Inc. | GENERIC cDNA OR PROTEIN ARRAY FOR CUSTOMIZED ASSAYS |
| US6284465B1 (en) | 1999-04-15 | 2001-09-04 | Agilent Technologies, Inc. | Apparatus, systems and method for locating nucleic acids bound to surfaces |
| US6268141B1 (en) | 1999-05-12 | 2001-07-31 | Beckman Coulter, Inc. | Immobilization of unmodified biopolymers to acyl fluoride activated substrates |
| EP1206577B1 (en) | 1999-08-13 | 2006-03-01 | Yale University | Binary encoded sequence tags |
| US6171797B1 (en) | 1999-10-20 | 2001-01-09 | Agilent Technologies Inc. | Methods of making polymeric arrays |
| US6372431B1 (en) | 1999-11-19 | 2002-04-16 | Incyte Genomics, Inc. | Mammalian toxicological response markers |
| DE19957827C2 (de) | 1999-11-25 | 2003-06-12 | Epigenomics Ag | Verwendung eines Oligomer-Arrays mit PNA- und/oder DNA-Oligomeren auf einer Oberfläche |
| US6383749B2 (en) | 1999-12-02 | 2002-05-07 | Clontech Laboratories, Inc. | Methods of labeling nucleic acids for use in array based hybridization assays |
| CA2400006A1 (en) | 2000-02-03 | 2001-08-09 | Research Development Foundation | Signaling aptamers that transduce molecular recognition to a differential signal |
| US6267152B1 (en) | 2000-02-18 | 2001-07-31 | Wisconsin Label Corporation | Hang tag and method of applying hang tag to an elongated object |
| US6376191B1 (en) | 2000-03-22 | 2002-04-23 | Mergen, Ltd. | Microarray-based analysis of polynucleotide sequence variations |
| WO2001088162A2 (en) | 2000-05-16 | 2001-11-22 | Genway Biotech, Inc. | Methods and vectors for generating antibodies in avian species and uses therefor |
| ES2281424T3 (es) | 2000-06-05 | 2007-10-01 | Novartis Vaccines And Diagnostics, Inc. | Micromatrices para llevar a cabo analisis proteomicos. |
| US6531283B1 (en) | 2000-06-20 | 2003-03-11 | Molecular Staging, Inc. | Protein expression profiling |
| US6386749B1 (en) | 2000-06-26 | 2002-05-14 | Affymetrix, Inc. | Systems and methods for heating and mixing fluids |
| US6380377B1 (en) | 2000-07-14 | 2002-04-30 | Applied Gene Technologies, Inc. | Nucleic acid hairpin probes and uses thereof |
| JP2002071687A (ja) | 2000-08-31 | 2002-03-12 | Canon Inc | 変異遺伝子のスクリーニング方法 |
| WO2002031463A2 (en) | 2000-08-31 | 2002-04-18 | Motorola, Inc. | High density column and row addressable electrode arrays |
| US7354721B2 (en) | 2000-09-22 | 2008-04-08 | Clontech Laboratories, Inc. | Highly sensitive proteomic analysis methods, and kits and systems for practicing the same |
| US6632611B2 (en) | 2001-07-20 | 2003-10-14 | Affymetrix, Inc. | Method of target enrichment and amplification |
| US6872529B2 (en) | 2001-07-25 | 2005-03-29 | Affymetrix, Inc. | Complexity management of genomic DNA |
| US7011945B2 (en) | 2001-12-21 | 2006-03-14 | Eastman Kodak Company | Random array of micro-spheres for the analysis of nucleic acids |
| US7011949B2 (en) | 2002-09-30 | 2006-03-14 | Agilent Technologies, Inc. | Methods and compositions for producing labeled probe nucleic acids for use in array based comparative genomic hybridization applications |
| US7028629B2 (en) | 2003-02-03 | 2006-04-18 | Richard Walcome | Self-sealing port light assembly |
| US20070037186A1 (en) | 2005-05-20 | 2007-02-15 | Yuqiu Jiang | Thyroid fine needle aspiration molecular assay |
| US7598052B2 (en) | 2005-10-11 | 2009-10-06 | The Regents Of The University Of Michigan | Expression profile of thyroid cancer |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| US20080090242A1 (en) * | 2006-09-29 | 2008-04-17 | Schering Corporation | Panel of biomarkers for prediction of fti efficacy |
| WO2009111881A1 (en) | 2008-03-13 | 2009-09-17 | British Columbia Cancer Agency Branch | Biomarkers for diagnosis of differentiated thyroid cancer |
| CN101608227A (zh) * | 2008-06-20 | 2009-12-23 | 上海主健生物工程有限公司 | 甲状腺癌遗传检测试剂盒 |
| JP2010022236A (ja) | 2008-07-16 | 2010-02-04 | Fujifilm Corp | 甲状腺癌の検出方法 |
| US20110230366A1 (en) * | 2008-08-12 | 2011-09-22 | Decode Genetics Ehf. | Genetic Variants Useful for Risk Assessment of Thyroid Cancer |
| GB2512153B (en) | 2008-11-17 | 2014-11-12 | Veracyte Inc | Methods and compositions of molecular profiling for disease diagnostics |
| WO2010124372A1 (en) * | 2009-04-29 | 2010-11-04 | Genomedx Biosciences, Inc. | Systems and methods for expression-based classification of thyroid tissue |
| JP6078339B2 (ja) * | 2009-05-07 | 2017-02-08 | ベラサイト インコーポレイテッド | 甲状腺状態の診断のための方法および組成物 |
| EP2480687B1 (en) | 2009-09-21 | 2015-01-28 | Paul Walfish | Methods and compositions for the diagnosis and treatment of thyroid cancer |
| EP2366800A1 (en) | 2010-03-01 | 2011-09-21 | Centrum Onkologii-Instytut im M. Sklodowskiej-Curie Oddzial w Gliwicach | Kit, method and use for the diagnosis of papillary thyroid cancer using a gene expression profile |
| MD4038C1 (ro) | 2010-03-03 | 2011-01-31 | Univ Nicolae Testemitanu | Procedeu de prognozare a riscului de dezvoltare a cancerului glandei tiroide |
| US20110275065A1 (en) * | 2010-05-07 | 2011-11-10 | Ranju Ralhan | Methods and compositions for the diagnosis and treatment of thyroid cancer |
| US20110312520A1 (en) | 2010-05-11 | 2011-12-22 | Veracyte, Inc. | Methods and compositions for diagnosing conditions |
| CN103468789A (zh) * | 2012-06-09 | 2013-12-25 | 解码（上海）生物医药科技有限公司 | 甲状腺癌易感基因无创检测试剂盒 |
| EP2925886B1 (en) | 2012-11-27 | 2019-04-24 | Pontificia Universidad Católica de Chile | Compositions and methods for diagnosing thyroid tumors |
-
2013
- 2013-11-26 EP EP13812260.1A patent/EP2925886B1/en active Active
- 2013-11-26 AU AU2013352339A patent/AU2013352339B2/en active Active
- 2013-11-26 CN CN201380071054.0A patent/CN104937111B/zh active Active
- 2013-11-26 US US14/647,284 patent/US10260103B2/en active Active
- 2013-11-26 WO PCT/US2013/071970 patent/WO2014085434A1/en not_active Ceased
- 2013-11-26 BR BR112015012239-6A patent/BR112015012239B1/pt active IP Right Grant
- 2013-11-26 CA CA2892822A patent/CA2892822C/en active Active
- 2013-11-26 MX MX2015006680A patent/MX367366B/es active IP Right Grant
- 2013-11-26 JP JP2015544190A patent/JP6309019B2/ja active Active
- 2013-11-26 NZ NZ709167A patent/NZ709167A/en unknown
- 2013-11-26 KR KR1020157017018A patent/KR102174578B1/ko active Active
-
2015
- 2015-06-26 ZA ZA2015/04663A patent/ZA201504663B/en unknown
-
2019
- 2019-02-15 US US16/277,950 patent/US20190241969A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10260103B2 (en) | 2019-04-16 |
| EP2925886A1 (en) | 2015-10-07 |
| BR112015012239A2 (enExample) | 2017-08-15 |
| WO2014085434A1 (en) | 2014-06-05 |
| ZA201504663B (en) | 2021-09-29 |
| AU2013352339B2 (en) | 2019-07-04 |
| MX2015006680A (es) | 2015-10-15 |
| CA2892822C (en) | 2023-08-08 |
| CN104937111A (zh) | 2015-09-23 |
| MX367366B (es) | 2019-08-16 |
| JP2016505247A (ja) | 2016-02-25 |
| AU2013352339A1 (en) | 2015-07-02 |
| HK1213947A1 (en) | 2016-07-15 |
| NZ709167A (en) | 2020-03-27 |
| EP2925886B1 (en) | 2019-04-24 |
| KR102174578B1 (ko) | 2020-11-06 |
| KR20150100698A (ko) | 2015-09-02 |
| CA2892822A1 (en) | 2014-06-05 |
| CN104937111B (zh) | 2018-05-11 |
| US20150299808A1 (en) | 2015-10-22 |
| BR112015012239B1 (pt) | 2022-07-19 |
| US20190241969A1 (en) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6309019B2 (ja) | 甲状腺腫瘍を診断するための組成物および方法 | |
| JP6285009B2 (ja) | 前立腺ガンの予後の検知及び判定のための組成物及び該検知及び判定方法 | |
| US20250137066A1 (en) | Compostions and methods for diagnosing lung cancers using gene expression profiles | |
| US20210010090A1 (en) | Method and system for predicting recurrence and non-recurrence of melanoma using sentinel lymph node biomarkers | |
| JP6711968B2 (ja) | 子宮体がんのリンパ節転移能の評価方法 | |
| JP6949315B2 (ja) | 肺扁平上皮癌と肺腺癌の鑑別評価方法 | |
| CN108660207B (zh) | 用于头颈部鳞状细胞癌诊断的循环长链非编码rna生物标志物和试剂盒及用途 | |
| JP2025539719A (ja) | 肝癌診断用ｄｎａメチル化マーカー及びその用途 | |
| WO2018098241A1 (en) | Methods of assessing risk of recurrent prostate cancer | |
| US20240052422A1 (en) | In-vitro method for diagnosing and predicting the aggressiveness of thyroid cancer, and the precision surgery options and type to be used to remove a tumour from a patient; kit; reagents forming the kit; and use of the reagents and use of molecular markers as part of the method | |
| CN103060348A (zh) | 用于检测原发性肝癌的复发潜力的基因标志物 | |
| JPWO2015115544A1 (ja) | 大腸がんの転移又は再発リスクの評価方法 | |
| WO2015105191A1 (ja) | リンパ節腫脹病変の評価方法 | |
| HK1213947B (en) | Compositions and methods for diagnosing thyroid tumors | |
| CN119570928A (zh) | 用于结直肠癌诊断和预后预测的lncRNA组合 | |
| WO2024163349A2 (en) | Kits and methods useful for prognosing, diagnosing, and treating prostate cancer | |
| JPWO2015115545A1 (ja) | 乳がんの転移又は再発リスクの評価方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161101 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161101 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180214 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180313 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6309019 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |